Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the activity of selexipag on Raynaud
attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis
(SSc).